bluebird bio, Inc (BLUE) Long-Term Debt to Capital Ratio
This price chart on GURU.Markets helps assess the stability of bluebird bio, Inc. (BLUE), a leader in the treatment of genetic blood pathologies, where the indicator stands at 0.00. The business relies on unique experience in drug implementation while contending with emerging technologies. Monetization is based on the ultra-high cost of one-time procedures, and the development strategy is currently focused on independently seeking investments due to a lack of liquidity.
Analytical breakdowns for bluebird bio, Inc. (BLUE)
The launch of the costly Lyfgenia therapy, amid FDA restrictions and a high cash burn rate, raises questions regarding the financial sustainability of bluebird bio, Inc. (BLUE). This metric compares the volume of liabilities with a maturity of over one year against total equity. By analyzing the long-term debt-to-equity trend, an investor assesses the business's degree of reliance on borrowed funds. An increase in this ratio signals a risk of liquidity shortages, while a decrease in the coefficient confirms the strengthening of the issuer's solvency.